Compare ERIE & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERIE | ILMN |
|---|---|---|
| Founded | 1925 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2B | 18.9B |
| IPO Year | 1995 | 2000 |
| Metric | ERIE | ILMN |
|---|---|---|
| Price | $296.79 | $128.82 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $114.93 |
| AVG Volume (30 Days) | 131.9K | ★ 1.5M |
| Earning Date | 10-30-2025 | 10-30-2025 |
| Dividend Yield | ★ 1.84% | N/A |
| EPS Growth | ★ 15.90 | N/A |
| EPS | ★ 12.39 | 4.46 |
| Revenue | $4,040,325,000.00 | ★ $4,288,000,000.00 |
| Revenue This Year | $9.98 | N/A |
| Revenue Next Year | $5.75 | $2.08 |
| P/E Ratio | ★ $23.93 | $28.91 |
| Revenue Growth | ★ 9.53 | N/A |
| 52 Week Low | $276.91 | $68.70 |
| 52 Week High | $456.93 | $153.06 |
| Indicator | ERIE | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 49.40 | 66.70 |
| Support Level | $292.47 | $124.27 |
| Resistance Level | $301.14 | $129.72 |
| Average True Range (ATR) | 5.59 | 3.90 |
| MACD | 2.03 | -0.41 |
| Stochastic Oscillator | 71.66 | 77.82 |
Erie Indemnity Co mainly performs services on behalf of the Erie Insurance Exchange relating to sales, underwriting, and issuance of policies. Erie Indemnity's results are tied to the performance of the Insurance Exchange, which principally provides automobile and homeowners insurance for individuals, along with multiperil, workers' compensation, and commercial automobile insurance for its commercial clients. The company operates exclusively in the United States.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.